Haemonetics (NYSE:HAE) Updates FY 2026 Earnings Guidance

Haemonetics (NYSE:HAE - Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 4.700-5.000 for the period, compared to the consensus EPS estimate of 4.540. The company issued revenue guidance of -, compared to the consensus revenue estimate of $1.4 billion.

Haemonetics Stock Performance

Shares of NYSE:HAE traded up $0.20 on Friday, reaching $68.21. The company's stock had a trading volume of 782,442 shares, compared to its average volume of 694,988. Haemonetics has a 52-week low of $55.30 and a 52-week high of $97.97. The stock has a market capitalization of $3.43 billion, a P/E ratio of 26.85, a PEG ratio of 1.11 and a beta of 0.32. The stock's 50-day moving average is $62.75 and its two-hundred day moving average is $71.39. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 EPS for the quarter, beating the consensus estimate of $1.22 by $0.02. Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. The firm had revenue of $330.60 million during the quarter, compared to the consensus estimate of $329.38 million. During the same period in the prior year, the business earned $0.90 EPS. The firm's revenue was down 3.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Haemonetics will post 4.55 EPS for the current year.

Wall Street Analyst Weigh In

HAE has been the topic of several recent research reports. Bank of America cut shares of Haemonetics from a "neutral" rating to an "underperform" rating and dropped their price objective for the company from $95.00 to $68.00 in a research note on Friday, February 7th. Raymond James reiterated a "strong-buy" rating and set a $105.00 price target (down from $115.00) on shares of Haemonetics in a research note on Friday. StockNews.com upgraded shares of Haemonetics from a "hold" rating to a "buy" rating in a research report on Monday, May 5th. JMP Securities dropped their target price on Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a research report on Friday, February 7th. Finally, Barrington Research reduced their price target on Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $97.89.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.